| Skin Cancer Vaccine -
25-09-2006, 08:47 PM
A new vaccine for late-stage melanoma may give hope to patients fighting the deadly cancer.
The vaccine is an immune-based approach to fighting cancer, which means it's intended to spark the body's own immune system response to the cancer. It's a whole new way to treat the disease.
A team of international researchers tested the vaccine on 23 patients with different kinds of late stage cancers that had spread throughout their bodies. Of nine patients with late stage melanoma, seven have survived between 17 months and 63 months. The average survival with the most severe form of melanoma is between six months and 12 months. One of the patients in this study had a complete immune response and remains disease free 32 months after the trial. Several other patients have stabilized their progression, or at least slowed it down.
A phase II study is currently underway. Researchers want to know more about how this new vaccine treatment strategy works for men and women with skin cancer that has spread to other locations.
Angel xenoMED | NDR “Nothing brings me more happiness than helping people in the society. It is a goal and an essential part of my life - a kind of destiny.” | 
Linear Mode
